Free Trial
→ Elon’s ultimate power move? (From Altimetry) (Ad)

Cybin Q2 2024 Earnings Report

Cybin logo
$9.91 -0.07 (-0.70%)
As of 01/31/2025 04:10 PM Eastern
Earnings HistoryForecast

Cybin EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.05
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Cybin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cybin Announcement Details

Quarter
Q2 2024
Date
11/14/2023
Time
N/A

Conference Call Resources

Cybin Earnings Headlines

Cybin: Paradigm Changing Ambitions
January 20, 2025 | seekingalpha.com
Cybin Inc. Achieves Breakthroughs in Mental Health Treatment
January 13, 2025 | tipranks.com
Elon’s Chosen Ones
Millions of Federal employees just got put on notice... In a single sweeping move, President Trump just offered to pay eight months' salary to any Federal worker who voluntarily quits. But according to one Boston-based think tank, who has consulted with the Pentagon, US Army, Harvard and who's work has been followed by many of the world's biggest banks...
February 1, 2025 | Altimetry (Ad)
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 9, 2025 | financialpost.com
Cybin Reveals Promising Results in Depression Treatment
December 10, 2024 | tipranks.com
Cybin Inc. Advances in Mental Health Treatments
November 25, 2024 | tipranks.com
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin (OTCMKTS:CYBN), a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

View Cybin Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles